Seema Sheoran
Stock Analyst at Rodman & Renshaw
(1.87)
# 3,198
Out of 4,442 analysts
5
Total ratings
40%
Success rate
2.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Seema Sheoran
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiated Coverage: Buy | $70 | $30.86 | +126.83% | 1 | Jun 3, 2026 | |
| AVXL Anavex Life Sciences | Initiated Coverage: Buy | $20 | $2.58 | +675.19% | 1 | May 4, 2026 | |
| CAMP Camp4 Therapeutics | Initiated Coverage: Buy | $7 | $4.34 | +61.29% | 1 | Apr 14, 2026 | |
| SABS SAB Biotherapeutics | Initiated Coverage: Buy | $13 | $3.87 | +235.92% | 1 | Apr 2, 2026 | |
| SGMT Sagimet Biosciences | Initiated Coverage: Buy | $28 | $7.06 | +296.60% | 1 | Mar 26, 2026 |
Neurogene
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $70
Current: $30.86
Upside: +126.83%
Anavex Life Sciences
May 4, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $2.58
Upside: +675.19%
Camp4 Therapeutics
Apr 14, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $4.34
Upside: +61.29%
SAB Biotherapeutics
Apr 2, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $3.87
Upside: +235.92%
Sagimet Biosciences
Mar 26, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $7.06
Upside: +296.60%